Supernus Pharmaceuticals to merge with Indivior in all-stock deal

M&A · PartnershipEarnings
โดย The Motley Fool·Read original
Summary · why it matters

Supernus Pharmaceuticals announced a definitive agreement to merge with Indivior Pharmaceuticals in a tax-free, all-stock transaction. The combined company will operate under the Supernus name and hold a portfolio of 11 FDA-approved drugs across neurology, addiction, and psychiatry. The deal, which is subject to shareholder and regulatory approvals, is expected to close in the fourth quarter and targets $125 million in annual cost synergies. Separately, Supernus reported second-quarter revenue of just over $219 million, a 32% increase driven by collaboration revenue from Biogen for Zurzuvae, but posted a net loss of over $58 million, or $1.01 per share, missing analyst profit estimates. The stock rose as much as 16% before closing 3% higher, outperforming the S&P 500's 1.5% gain.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 3 stocks
Supernus Pharmaceuticals Inc
SUPN
▲ PositiveCapitalrelevance

Supernus announced a merger with Indivior, targeting $125 million in annual cost synergies, and reported strong revenue growth, though it missed profit estimates.

Indivior PLC Ordinary Shares
INDV
▲ PositiveCapitalrelevance

Indivior is merging with Supernus in an all-stock deal, creating a combined company with a larger portfolio and cost synergies.

Biogen Inc
BIIB
▲ PositiveDemandrelevance

Collaboration revenue from Biogen for Zurzuvae drove Supernus's revenue growth, indicating strong product demand.

© 2026 MarketDXNews